Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Scholar Rock Holding Corporation

Market Cap 5.28B 4.56B 4.2B 3.94B 7.38B 506B 7.5B 49.8B 19.37B 244B 19.83B 19.4B 846B P/E Ratio 2026 *
-14.1x
P/E Ratio 2027 * -17.5x
Enterprise Value 4.98B 4.3B 3.96B 3.71B 6.96B 477B 7.07B 46.95B 18.26B 230B 18.7B 18.3B 797B EV / Sales 2026 *
765x
EV / Sales 2027 * 33x
Free-Float
99.25%
Yield 2026 *
-
Yield 2027 * -
1 day+1.36%
1 week+0.11%
Current month-9.35%
1 month-7.65%
3 months-0.20%
6 months-0.80%
Current year+1.45%
1 week 43.23
Extreme 43.23
47.69
1 month 43.23
Extreme 43.23
52.18
Current year 38.75
Extreme 38.75
52.18
1 year 27.07
Extreme 27.07
52.18
3 years 5.93
Extreme 5.93
52.18
5 years 4.32
Extreme 4.325
52.18
10 years 4.32
Extreme 4.325
70
Manager TitleAgeSince
Chief Executive Officer 59 2025-04-26
Director of Finance/CFO 62 2025-04-26
Chief Operating Officer 58 2025-04-26
Director TitleAgeSince
Chairman 59 2017-06-30
Director/Board Member 52 2014-07-31
Director/Board Member 77 2016-09-30
Date Insider Type Main position Quantity % Market Cap.
06-03
Samsara BioCapital LLC
OtherCompany 0 0%
06-03Free

Director

11,149 0.0097%
06-03Free

Director

11,149 0.0097%
Change 5-day change 1-year change 3-year change Capi.($)
+1.36%+0.11%+29.84%+538.43% 5.28B
+1.65%+11.53%+52.68%+112.78% 54.82B
+0.03%-1.80%+49.57%+43.94% 43.27B
+3.93%+1.23%-16.23%-18.04% 21.79B
+5.27%-6.87%+6.37%+388.48% 19.92B
+0.81%-8.38%+12.77%-33.24% 15.67B
+0.53%+6.07%+8.13%-39.59% 15.26B
+1.75%+3.68%+25.82%+178.65% 13.22B
-5.27%+3.89%+90.88%+208.02% 11.58B
-1.74%-1.05%+12.88% - 11.94B
Average +0.83%-0.64%+27.27%+153.27% 21.27B
Weighted average by Cap. +1.18%+1.10%+32.13%+109.15%

Financials

2026 *2027 *
Net sales 6.51M 5.63M 5.18M 4.85M 9.09M 624M 9.24M 61.38M 23.88M 301M 24.44M 23.92M 1.04B 149M 129M 119M 111M 209M 14.31B 212M 1.41B 548M 6.9B 561M 549M 23.93B
Net income -410M -354M -326M -305M -572M -39.23B -582M -3.86B -1.5B -18.91B -1.54B -1.5B -65.58B -356M -308M -283M -266M -498M -34.12B -506M -3.36B -1.31B -16.44B -1.34B -1.31B -57.04B
Net Debt -302M -261M -240M -225M -422M -28.92B -429M -2.85B -1.11B -13.94B -1.13B -1.11B -48.35B -356M -307M -283M -265M -497M -34.05B -505M -3.35B -1.3B -16.41B -1.33B -1.31B -56.92B
Logo Scholar Rock Holding Corporation
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.
Employees
289
Date Price Change Volume
26-06-11 44.69 $ +1.36% 975,924
26-06-10 44.09 $ -3.27% 1,457,699
26-06-09 45.58 $ +4.06% 994,648
26-06-08 43.80 $ -1.13% 811,977
26-06-05 44.30 $ -2.27% 1,153,268
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
44.09USD
Average target price
59.31USD
Spread / Average Target
+34.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SRRK Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!